The Preventive Effect of Oxytocin to Cisplatin-induced Neurotoxicity: an Experimental Rat Model

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Feb 18

PMID 25688351

Citations 23

Authors

Tulay Akman

Levent Akman

Oytun Erbas

Mustafa Cosan Terek

Dilek Taskiran

Aydin Ozsaran

Affiliations

Soon will be listed here.

Abstract

Peripheral neurotoxicity is a frequent dose-limiting side effect of the chemotherapeutic agent cisplatin. This study was conducted to investigate the preventive effect of oxytocin (OT) on cisplatin-induced neurotoxicity in rats. Forty-four adult female rats were included in the study. Thirty-six rats were administered intraperitoneally (i.p.) single dose cisplatin 10 mg/kg and divided in to 3 groups. The first group (n=12) received saline i.p., whereas the second group (n=12) and the third group (n=12) were injected with 80 µg/kg and 160 µg/kg OT, respectively, for 10 days. The remaining 8 rats served as the control group. Electromyography (EMG) studies were recorded and blood samples were collected for the measurement of plasma lipid peroxidation (malondialdehyde; MDA), tumor necrosis factor (TNF)-α, and glutathione (GSH) levels. EMG findings revealed that compound muscle action potential amplitude was significantly decreased and distal latency was prolonged in the nontreated cisplatin-injected rats compared with the control group (P<0.005). Also, nontreated cisplatin-injected rats showed significantly higher TNF-α and MDA levels and lower GSH level than control group. The administration of OT significantly ameliorated the EMG alterations, suppressed oxidative stress and inflammatory parameters, and increased antioxidative capacity. We suggest that oxytocin may have beneficial effects against cisplatin-induced neurotoxicity.

Citing Articles

Deferiprone ameliorates cisplatin induced peripheral neurotoxicity via ferritinophagy adjustment.

Seddiek H, Hanna M, Hamoud A, Elbaset M, Akabawy A, Kotb M Sci Rep. 2025; 15(1):4485.

PMID: 39915547 PMC: 11802739. DOI: 10.1038/s41598-025-87628-x.

Captopril attenuates oxidative stress and neuroinflammation implicated in cisplatin-induced cognitive deficits in rats.

Mostafa F, Mantawy E, Said R, Azab S, El-Demerdash E Psychopharmacology (Berl). 2025; 242(3):563-578.

PMID: 39809925 PMC: 11861019. DOI: 10.1007/s00213-024-06706-6.

Effects of Oxytocin on Glutamate Mediated Neurotoxicity in Neuroblastoma Cell Culture.

Ozgur B, Vural K, Tuglu M Noro Psikiyatr Ars. 2024; 61(1):24-29.

PMID: 38496224 PMC: 10943934. DOI: 10.29399/npa.28377.

Sea urchin (Diadema savignyi) extract as a novel protective agent against cisplatin induced neurotoxicity in rats.

Khalil E, Swelim H, El-Tantawi H, Abdellatif A BMC Pharmacol Toxicol. 2023; 24(1):11.

PMID: 36823675 PMC: 9948489. DOI: 10.1186/s40360-023-00651-4.

Vitamin C (Ascorbic acid) protects from neuropathy caused by cisplatin, through enhanced heat shock protein-70 and reduced oxidant effect.

Pala E, Pala H, Ekmekci S, Erbas O Rev Assoc Med Bras (1992). 2022; 68(8):1017-1022.

PMID: 36134830 PMC: 9574981. DOI: 10.1590/1806-9282.20220032.

References

Orhan B, Yalcin S, Nurlu G, Zeybek D, Muftuoglu S . Erythropoietin against cisplatin-induced peripheral neurotoxicity in rats. Med Oncol. 2004; 21(2):197-203. DOI: 10.1385/MO:21:2:197. View

Jankowski M, Wang D, Hajjar F, Mukaddam-Daher S, McCANN S, Gutkowska J . Oxytocin and its receptors are synthesized in the rat vasculature. Proc Natl Acad Sci U S A. 2000; 97(11):6207-11. PMC: 18583. DOI: 10.1073/pnas.110137497. View

Tomiwa K, Nolan C, CAVANAGH J . The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol. 1986; 69(3-4):295-308. DOI: 10.1007/BF00688308. View

Mollman J . Cisplatin neurotoxicity. N Engl J Med. 1990; 322(2):126-7. DOI: 10.1056/NEJM199001113220210. View

Cavaletti G, Tredici G, Marmiroli P, Petruccioli M, Barajon I, Fabbrica D . Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992; 84(4):364-71. DOI: 10.1007/BF00227662. View

Leibbrandt M, Wolfgang G, Metz A, Ozobia A, Haskins J . Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995; 48(3):761-70. DOI: 10.1038/ki.1995.348. View

Gill J, Windebank A . Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998; 101(12):2842-50. PMC: 508875. DOI: 10.1172/JCI1130. View

Petersson M, Lundeberg T, Sohlstrom A, Wiberg U, Uvnas-Moberg K . Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol. 1998; 357(6):701-4. DOI: 10.1007/pl00005227. View

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

10.

van Ruijven M, de Groot J, Klis S, Smoorenburg G . The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res. 2005; 205(1-2):241-8. DOI: 10.1016/j.heares.2005.03.023. View

11.

Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M . Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci. 2006; 100(1):65-72. DOI: 10.1254/jphs.fp0050661. View

12.

Gimpl G, Fahrenholz F . The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001; 81(2):629-83. DOI: 10.1152/physrev.2001.81.2.629. View

13.

Kaushal G, Kaushal V, Hong X, Shah S . Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 2001; 60(5):1726-36. DOI: 10.1046/j.1523-1755.2001.00026.x. View

14.

Moosmann B, Behl C . Secretory peptide hormones are biochemical antioxidants: structure-activity relationship. Mol Pharmacol. 2002; 61(2):260-8. DOI: 10.1124/mol.61.2.260. View

15.

Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G . Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003; 21(5):927-31. DOI: 10.1200/JCO.2003.05.139. View

16.

Tan D, Manchester L, Terron M, Flores L, Reiter R . One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. J Pineal Res. 2007; 42(1):28-42. DOI: 10.1111/j.1600-079X.2006.00407.x. View

17.

Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C . Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007; 130(Pt 4):1076-88. DOI: 10.1093/brain/awl356. View

18.

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

19.

So H, Kim H, Lee J, Park C, Kim Y, Kim E . Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol. 2007; 8(3):338-55. PMC: 2538433. DOI: 10.1007/s10162-007-0084-9. View

20.

Garcia J, Cata J, Dougherty P, Smith R . Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia. Endocrinology. 2007; 149(2):455-60. PMC: 2219295. DOI: 10.1210/en.2007-0828. View